{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:35:22Z","timestamp":1761989722279,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40262-023-01214-w","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T19:02:46Z","timestamp":1678561366000},"page":"609-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist"],"prefix":"10.1007","volume":"62","author":[{"given":"Islam","family":"Younis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deqing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2775","authenticated-orcid":false,"given":"Ahmed A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70:788\u2013801.","journal-title":"Hepatology"},{"key":"1214_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72:58\u201371.","journal-title":"Hepatology"},{"key":"1214_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73:625\u201343.","journal-title":"Hepatology"},{"key":"1214_CR4","doi-asserted-by":"crossref","first-page":"574A","DOI":"10.1002\/hep.28316","volume":"63","author":"B Kirby","year":"2016","unstructured":"Kirby B, Djedjos CS, Birkebak J, et al. Evaluation of the safety and pharmacokinetic effects of the oral, non-steroidal farnesoid X receptor agonist GS-9674 in healthy volunteers. Hepatology. 2016;63:574A.","journal-title":"Hepatology"},{"key":"1214_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13469","author":"IR Younis","year":"2023","unstructured":"Younis IR, Kirby BJ, Billin AN, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal farnesoid X receptor agonist, in healthy volunteers. Clin Transl Sci. 2023. https:\/\/doi.org\/10.1111\/cts.13469.","journal-title":"Clin Transl Sci"},{"key":"1214_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms21197023","volume":"21","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li P, Zhang Z, Wang Z, Liu L, Liu X. Prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and enzymes. Int J Mol Sci. 2020;21:7023.","journal-title":"Int J Mol Sci"},{"key":"1214_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cpt.1435","volume":"105","author":"A Tornio","year":"2019","unstructured":"Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 2019;105:1345\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"1214_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/cpt.1073","volume":"104","author":"JD Lutz","year":"2018","unstructured":"Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104:1182\u201390.","journal-title":"Clin Pharmacol Ther"},{"key":"1214_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/pharmaceutics13111961","volume":"13","author":"A Czyrski","year":"2021","unstructured":"Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka FK. The overview on the pharmacokinetic and pharmacodynamic interactions of triazoles. Pharmaceutics. 2021;13:1961.","journal-title":"Pharmaceutics"},{"key":"1214_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2125.2010.03722.x","volume":"70","author":"DG Bailey","year":"2010","unstructured":"Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010;70:645\u201355.","journal-title":"Br J Clin Pharmacol"},{"key":"1214_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006761","volume":"96","author":"PJ Patel","year":"2017","unstructured":"Patel PJ, Hayward KL, Rudra R, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: implications for disease severity and management. Medicine (Baltimore). 2017;96: e6761.","journal-title":"Medicine (Baltimore)"},{"key":"1214_CR12","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s11095-014-1305-7","volume":"31","author":"Y Shirasaka","year":"2014","unstructured":"Shirasaka Y, Mori T, Murata Y, Nakanishi T, Tamai I. Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1. Pharm Res. 2014;31:2035\u201343.","journal-title":"Pharm Res"},{"key":"1214_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/00498250701278442","volume":"37","author":"R Nakagomi-Hagihara","year":"2007","unstructured":"Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica. 2007;37:474\u201386.","journal-title":"Xenobiotica"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01214-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T05:27:00Z","timestamp":1681104420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01214-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01214-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"16 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Gilead Sciences, Inc. Writing and editorial support were provided by Helen Rodgers, PhD, of AlphaScientia, LLC, San Francisco, CA, USA, and was funded by Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EW, IY, GS, DX, TRW, AAO are employees of, and may own stock in, Gilead Sciences, Inc. CN and BJK were employees of Gilead Sciences, Inc., at the time of study and may own stock in Gilead Sciences, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocol was reviewed and approved by an institutional review board (IRB; Schulman IRB; 4445 Lake Forest Drive, Suite 300; Cincinnati, OH 45242).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written, informed consent prior to study participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved this manuscript for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anonymized individual participant data will be shared upon request for research purposes dependent upon the nature of the request, the merit of the proposed research, the availability of the data, and its intended use. The full data sharing policy for Gilead Sciences, Inc., can be found at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material code availability"}},{"value":"IY: Writing\u2014original draft preparation; EW: Writing\u2014original draft preparation; CN: Writing\u2014review and editing; BK: Writing\u2014review and editing; GS: Writing\u2014review and editing; DX: Writing\u2014review and editing; TW: Writing\u2014review and editing; AAO: Writing\u2014review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}